Inaktiver Wert

Andere Sprachen Onconova Therapeutics Inc Nasdaq

Aktien

US68232V3069

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

Traws Pharma : Targeting the RAS/RAF/PI3K pathway for CD40 induction in melanoma cells to overcome resistance to anti-PD1 immunotherapies	07.05.
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy	07.05.
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy	07.05.
North American Morning Briefing : Focus Turns to -2-	04.04.
Traws Pharma, Inc. Announces Chief Executive Office Changes	04.04.
Traws Pharma, Inc. Announces Board Changes	04.04.
Onconova Therapeutics Shares Drop; Company to Merge With Trawsfynydd Therapeutics	02.04.
Traws Pharma Announces New Employee Inducement Grants	02.04.
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company	02.04.
Onconova Therapeutics, Inc and Trawsfynydd Therapeutics, Inc. Announce Management Appointments for the Combined Company Traws Pharma, Inc	02.04.
Onconova Therapeutics, Inc. completed the acquisition of Trawsfynydd Therapeutics, Inc.	02.04.
Onconova Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
Traws Pharma, Inc. announced that it has received $14 million in funding from OrbiMed Advisors LLC, Torrey Pines	01.04.
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024	08.03.
Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma	12.12.
Onconova TherapeuticsNarazaciclib Ash Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma	12.12.
Onconova Therapeutics Preclinical Narazaciclib Data At SABCS Highlights Differentiated Anti-Tumor Activity V. Other CDK4/6i's	11.12.
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s	08.12.
Onconova Therapeutics? Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i?s	08.12.
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets Nineteenth Annual Emerging Growth Equity Conference	29.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Onconova Therapeutics Inc Nasdaq

Aktien

US68232V3069

Andere Sprachen

Filter